Difference between revisions of "Semuloparin (AVE-5026)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "http://www.nejm.org" to "https://www.nejm.org") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Investigational" to "Category:Investigational drugs") |
||
| Line 19: | Line 19: | ||
[[Category:Ultralow molecular weight heparins]] | [[Category:Ultralow molecular weight heparins]] | ||
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Revision as of 17:40, 3 February 2019
General information
Class/mechanism: Hemisynthetic ultra low molecular weight heparin (ULMWH), binds to antithrombin III, accelerating its activity and inhibiting factor Xa, factor IIa, and thrombin.[1][2]
Route: SC
Extravasation: n/a
Patient drug information
No information available.
References
- ↑ Semuloparin (AVE5026) manufacturer's website
- ↑ Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9. link to original article PubMed